Literature DB >> 10227922

Postoperative protein sparing.

D W Wilmore1.   

Abstract

Postoperative nitrogen sparing refers to a therapy that decreases net nitrogen loss from the body following an operation. Protein sparing has long been regarded as a surrogate marker for improved outcome, but a critical review of the evidence indicates that this relation is difficult to establish, especially in the short term. Thus, specific endpoints that evaluate outcome are needed to determine the efficacy of a specific therapy that spares protein. Cost effectiveness must also be considered. A variety of therapies were evaluated using protein-sparing, efficiency, and cost criteria. Evidence was reviewed for glucose, amino acids, parenteral nutrition, enteral nutrition, growth hormone, and glutamine administered during the perioperative period. Only three areas could be identified that spared nitrogen and provided efficacy: (1) preoperative total parenteral nutrition (TPN) for 7 to 10 days before operation in a depleted patient (</=15% body weight loss); (2) the use of growth hormone with nutritional support to promote wound healing (especially in burns) and possibly to enhance muscle strength (particularly in the elderly); and (3) the use of glutamine-supplemented TPN in severely ill surgical patients to decrease mortality. The issue of early tube feeding in trauma patients is still confusing. This therapy must be evaluated by an appropriate study in trauma patients that compares a tube-fed group with an unfed control group. Only by demonstrating improved outcomes and enhanced cost saving with our protein-sparing therapy can we continue to enhance the care of our surgical patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10227922     DOI: 10.1007/pl00012345

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  6 in total

1.  Expression of growth hormone receptor and its mRNA in hepatic cirrhosis.

Authors:  Hong-Tao Wang; Shuang Chen; Jie Wang; Qing-Jia Ou; Chao Liu; Shu-Sen Zheng; Mei-Hai Deng; Xiao-Ping Liu
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

2.  Effectiveness of Recombinant Human Growth Hormone for Pharyngocutaneous Fistula Closure.

Authors:  Nurten Kucuk; Murat Sari; Ahmet Midi; Ali Cemal Yumusakhuylu; Ozan Findik; Adem Binnetoglu
Journal:  Clin Exp Otorhinolaryngol       Date:  2015-11-10       Impact factor: 3.372

3.  Protective effects of recombinant human growth hormone on cirrhotic rats.

Authors:  Shuang Chen; Hong-Tao Wang; Bin Yang; Yu-Ru Fu; Qing-Jia Ou
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

4.  Effects of growth hormone and insulin-like growth factor-1 on postoperative muscle and substrate metabolism.

Authors:  Folke Hammarqvist; Ingmar Wennström; Jan Wernerman
Journal:  J Nutr Metab       Date:  2009-11-22

5.  Examination of a nutritional treatment pathway according to pretreatment health status and stress levels of patients undergoing hematopoietic stem cell transplantation.

Authors:  Takashi Aoyama; Osamu Imataki; Akifumi Notsu; Takashi Yurikusa; Koki Ichimaru; Masanori Tsuji; Kanako Yoshitsugu; Masafumi Fukaya; Terukazu Enami; Takashi Ikeda
Journal:  PLoS One       Date:  2022-08-01       Impact factor: 3.752

6.  Characteristics of sarcopenia after distal gastrectomy in elderly patients.

Authors:  Sadamu Takahashi; Shota Shimizu; Satoshi Nagai; Hiroshi Watanabe; Yuuko Nishitani; Yasuro Kurisu
Journal:  PLoS One       Date:  2019-09-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.